Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)

Launched by CENTRO CARDIOPATICI TOSCANI · Jun 5, 2013

Keywords

ClinConnect Summary

This is a prospective, single-centre, randomized study, designed to compare the nephro-protective effects of high-dose atorvastatin and high-dose rosuvastatin on the incidence of Contrast Induced-Acute Kidney Injury (CI-AKI). Consecutive statin-naïve patients admitted in the investigators institution for non-ST elevation Acute Coronary Syndrome (NSTE-ACS) and scheduled for early invasive strategy will be eligible.

Patients are randomized into two groups: 1) high-dose rosuvastatin (40 mg on-admission followed by 20 mg/day); 2) high-dose atorvastatin (80 mg on-admission followed by 40 mg/day...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All consecutive statin-naive patients with non ST-elevation acute coronary syndrome admitted to our institution and scheduled for early invasive strategy are considered for enrollment
• Exclusion Criteria:
• • Current statin treatment
• • High-risk features warranting emergency coronary angiography (within 2 hours)
• • Acute renal failure or end-stage renal failure requiring dialysis or serum creatinine ≥ 3 mg/dl
• • Severe comorbidities which precluded early invasive strategy
• • Contraindications to statin treatment
• • Contrast media administration within the last 10 days
• • Pregnancy
• • Refusal of consent